Crescita Therapeutics Inc.
CTX.TO
TSX
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -13.37% | 48.59% | 50.79% | -33.49% | 41.97% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -13.37% | 48.59% | 50.79% | -33.49% | 41.97% |
| Cost of Revenue | -27.37% | 54.47% | 28.52% | -34.95% | 164.14% |
| Gross Profit | 13.29% | 43.73% | 69.26% | -31.93% | -24.50% |
| SG&A Expenses | 19.12% | -7.46% | -3.35% | -15.57% | 3.45% |
| Depreciation & Amortization | -40.51% | 21.85% | 14.81% | -13.87% | -164.86% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -11.27% | 15.42% | 8.88% | -24.56% | 44.03% |
| Operating Income | -42.72% | 86.31% | 155.23% | -36.48% | -130.45% |
| Income Before Tax | -300.56% | 171.97% | 185.24% | -39.87% | -464.35% |
| Income Tax Expenses | 165.00% | -- | -- | -- | -106.91% |
| Earnings from Continuing Operations | -340.80% | 171.97% | 185.24% | -39.87% | -4.90% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -340.80% | 171.97% | 185.24% | -39.87% | -4.90% |
| EBIT | -42.72% | 86.31% | 155.23% | -36.48% | -130.45% |
| EBITDA | -253.88% | 125.57% | 225.09% | -92.52% | -119.51% |
| EPS Basic | -349.18% | 173.60% | 187.64% | -43.88% | -10.91% |
| Normalized Basic EPS | 86.36% | 201.22% | 187.16% | -43.92% | -512.50% |
| EPS Diluted | -297.10% | 173.60% | 179.18% | -43.88% | 1.43% |
| Normalized Diluted EPS | 86.36% | 201.22% | 186.70% | -43.92% | -512.50% |
| Average Basic Shares Outstanding | -2.66% | -2.26% | -2.62% | -2.88% | -4.33% |
| Average Diluted Shares Outstanding | -2.66% | -2.20% | -2.09% | -2.88% | -4.33% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |